Elevated coffee consumption is associated with a lower risk of elevated liver fibrosis biomarkers in patients treated for chronic hepatitis B (ANRS CO22 Hepather cohort)
Autor: | Tangui Barré, Hélène Fontaine, Clémence Ramier, Vincent Di Beo, Stanislas Pol, Patrizia Carrieri, Fabienne Marcellin, Carole Cagnot, Céline Dorival, Jessica Zucman-Rossi, Fabien Zoulim, Fabrice Carrat, Camelia Protopopescu |
---|---|
Přispěvatelé: | Gestionnaire, HAL Sorbonne Université 5, Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), ANRS France Recherche Nord & sud Sida-hiv hépatites, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité), Cancer Research and Personalized Medicine - CARPEM [Paris], Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Necker - Enfants Malades [AP-HP], Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hospices Civils de Lyon (HCL), École Pratique des Hautes Études (EPHE) |
Jazyk: | angličtina |
Rok vydání: | 2022 |
Předmět: |
Liver Cirrhosis
MESH: Hepatitis B Chronic Liver fibrosis Critical Care and Intensive Care Medicine Severity of Illness Index Coffee MESH: gamma-Glutamyltransferase MESH: Aspartate Aminotransferases Hepatitis B Chronic MESH: Cross-Sectional Studies Caffeine MESH: Severity of Illness Index Humans Aspartate Aminotransferases MESH: Platelet Count Retrospective Studies Nutrition and Dietetics MESH: Humans Platelet Count MESH: Coffee MESH: Retrospective Studies [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology gamma-Glutamyltransferase Hepatitis B [SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology Cross-Sectional Studies [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie MESH: Biomarkers [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie France MESH: Liver Cirrhosis Biomarkers |
Zdroj: | Clinical Nutrition Clinical Nutrition, 2022, 41 (3), pp.610-619. ⟨10.1016/j.clnu.2022.01.016⟩ |
ISSN: | 0261-5614 |
Popis: | International audience; Background and aimsPatients chronically infected with hepatitis B virus (HBV) are at high risk of liver fibrosis, cirrhosis and liver cancer, despite recent therapeutic advances. It is therefore crucial to find non-pharmaceutical options for liver fibrosis prevention in this population. Using cross-sectional data from the ANRS CO22 Hepather cohort, we aimed to identify socio-demographic and modifiable risk factors for significant fibrosis in chronic HBV patients.MethodsLogistic regression or Firth's penalized maximum likelihood logistic regression (according to outcome prevalence) multivariable models were used to test for associations between explanatory variables and significant fibrosis, as assessed by three non-invasive markers: aspartate aminotransferase to platelet ratio index (APRI), FIB-4, and gamma glutamyltransferase to platelet ratio (GPR). Analyses were stratified by HBV treatment status.ResultsThe study population comprised 2065 untreated and 1727 treated chronic HBV patients. Elevated coffee consumption was consistently associated with a lower risk of elevated fibrosis biomarkers in all three treated-participant models, suggesting a dose-response relationship (adjusted odds ratios for ≥3 cups/day versus 0 cups/day: 0.16, 0.35 and 0.62, p ≤ 0.002, according to APRI, FIB-4 and GPR, respectively). Other modifiable risk factors included tobacco and alcohol use.ConclusionElevated coffee consumption was consistently associated with a lower risk of significant liver fibrosis, as assessed by three non-invasive markers in treated chronic HBV patients. This result can be immediately used in real-world situations, as increasing coffee consumption may be beneficial for patients at risk of advanced liver disease |
Databáze: | OpenAIRE |
Externí odkaz: |